ES · Q4 2025 Earnings

Q2 anchor → Q3 anchor → Q4 anchor: Contingent posture → Strategic offense → Transformational year, contingency stack.

The narrative arc on 2026 has flipped from offense to transition in a single quarter. Last quarter management was leaning into load growth outpacing distributed generation, raising the FY25 midpoint, and unveiling $1.5–$2B of incremental capex. This quarter, 2026 is being pre-positioned as "a truly transformational year" with growth explicitly "more moderate" and an inflection promised in 2027+. The verbatim hedge — "we view the 2026 headwinds as transitory and not reflective of the underlying strength of the business" — is doing a lot of work; management is attempting to control the FY26 narrative before the market does the math on 0.8–4.0% implied growth being well below the 5–7% long-term target.

Long-term EPS growth was reaffirmed at 5–7% but quietly rebased from 2024 to 2025. In Q2 and Q3, the 5–7% target was off a $4.57 2024 base. This quarter, the base resets to $4.76 (2025). On its own, this is a normal annual roll-forward — but combined with a $4.80–$4.95 FY26 guide that requires the entire FY27–FY28 ramp to hit the "upper half" by 2028, the rebase makes the 2028 destination meaningfully easier to portray and slightly harder to verify in the interim. The Wells Fargo and UBS exchanges (next section) confirm that management is now anchoring "upper half" to a 2027 base, not 2026 — an important clarification that ought to be reiterated in writing.

Balance-sheet language has shifted from confidence to vigilance. Q3 introduced the FFO/debt ratio as a proactive disclosure with a quantified buffer. Q4 withdraws it and replaces the quantification with the phrase "laser focused on improving our balance sheet" — used twice. The repetition signals awareness of vulnerability, not strength. The introduction of "junior subordinated notes, minority interest sale, or minority light capital structured financing transactions" as live alternatives makes explicit that the capital plan now requires contingent funding structures beyond common equity, regardless of how Aquarion resolves.

Aquarion has moved from "expected to close by year-end 2025" to "uncertainty surrounding the sale, fallback rate case filed." Q3 still committed to a year-end 2025 close pending the November 19 PURA decision. That date came and went; this quarter the company has submitted a notice of intent to file an Aquarion rate case for $88M as a contingency, and management is openly framing two paths. The rate-case filing is itself an admission that the sale is no longer expected to close on the original schedule — a slip that materially changes the financing cadence relative to last quarter's framing.

The capex/regulatory linkage has tightened from "constructive shift" to "multiple transformational processes requiring active negotiation." Last quarter Connecticut was framed as thawing. This quarter the regulatory landscape is framed as "changing" with three concurrent processes — Aquarion, storm-cost securitization (PURA decision July), and AMI ($1B placeholder, cost estimate "stale") — each of which must clear independently for the 2027 inflection to materialize. The Q3 brief's promise of strategic offense has not been retracted but has been deferred by a year.